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Background: TRAIL and IFNγ are promising anti-cancer cytokines and it has been shown that IFNγ may sensitize
cancer cells to TRAIL. Adipose derived mesenchymal stem cells (ADSCs) are attractive vehicles for delivering anti-cancer
agents. In this study, we evaluated the therapeutic potential of PhiC31 (φC31) recombinase and/or piggyBac transposase
(pBt) modified ADSCs expressing either TRAIL, IFNγ, or co-expressing TRAIL/IFNγ in mouse models of melanoma.
Methods: The expression and bioactivity of mouse IFNγ and TRAIL in φC31 and pBt modified cells were confirmed. We
examined the effects of modified ADSCs on signal intensity of red fluorescence protein expressed by melanoma cells
in subcutaneous tumors or established lung metastases and on survival (6 mice per group). We also conducted a flow
cytometric analysis of systemic CD4+CD25+FOXP3+ T regulatory cells (Tregs) and histological analysis of melanoma
tumors. Data were analyzed by Student t test, ANOVA, and log-rank tests. All statistical tests were two-sided.
Results: We demonstrated non-viral DNA-integrating vectors can be used for stable transgene expression. IFNγ inhibited
melanoma cell growth in vitro probably via IFNγ-induced JAK/STAT1 signaling pathway activation. Murine TRAIL induced
apoptosis in the human cell lines CAOV-4 and Ej-138, while MCF7 and B16F10 cells appeared to be insensitive to TRAIL.
Treatment of melanoma cells with IFNγ did not influence their response to TRAIL. In contrast, results from in vivo studies
showed that IFNγ-expressing ADSCs, engrafted into tumor stroma, inhibited tumor growth and angiogenesis, prevented
systemic increase of Tregs, increased PD-L1 expression and CD8+ infiltration (but not interleukin-2+ cells), and prolonged
the survival of mice (68 days, 95% confidence interval [CI] =52 to 86 days compared to 36 days, 95% CI =29 to 39 days for
control, P < .001).
Conclusions: For the first time, we employed DNA integrating vectors for safe and stable modification of MSCs. Our data
indicate potential of non-virally modified IFNγ-expressing ADSCs for treatment of melanoma through direct effects of IFNγ.
This study may have a significant role in the management of cancer in the future.
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Mesenchymal stem cells (MSCs) are emerging as prom-
ising tools for combined cancer gene/cell therapies since
they have the unique ability of targeting tumor cells [1].
Several recent studies have successfully used viral-based
gene transfer approaches to modify MSCs. However,
immunogenicity, risk of insertional mutagenesis, and
accidental production of self-replicating viruses are of
concern and remain a problem for viral systems [2].
Non-viral gene delivery methods represent a simpler
and safer alternative, as long-term expression of the
therapeutic genes can be achieved though their stable
integration into the host genome using DNA-based
gene transfer vectors. Commonly used non-viral inte-
grating vectors permanently integrate DNA into the
host genome via either a recombinase or transposase
[3]. PhiC31 (φC31) recombinase and piggyBac transpo-
sase (pBt) are two representatives of DNA-based gene
transfer vectors that are under intensive development
[4,5]. The site-specific recombinase of bacteriophage
φC31 integrates the complete plasmid construct carry-
ing an attB sequence into pseudo attP site in the mam-
malian genome [2]. Compared to φC31, pBt insert only
the transposon cassette including the transgenes situ-
ated inside of terminal repeat elements (TREs) [6]. We
used the φC31 and pBt systems to achieve long term
gene expression of therapeutic agents in murine adipose
derived MSCs (ADSCs).
The cytokine type II interferon (IFNγ) can be used as
a therapeutic agent as it exerts a variety of different
anti-tumor effects, including inhibition of cancer cell
proliferation, repression of tumor angiogenesis, and the
induction of tumor cell apoptosis [7,8]. IFNγ also stimu-
lates the host immune response and enhances tumor
cell apoptosis via tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) [9]. TRAIL in its
role as a death ligand binds to the surface death recep-
tors (DR; DR1 and DR2) and induces apoptosis in a var-
iety of neoplastic cells while sparing most normal cells.
Cancer cells have variable levels of sensitivity to TRAIL-
mediated apoptosis [10] and studies have shown that
IFNγ pre-treatment can sensitize some of the resistant
cancer lines to TRAIL [11-15]. Besides, IFNγ/TRAIL
combination immunotherapy has been shown to syner-
gistically induce tumor cell death [16]. However, to yield
significant anti-tumor activity, multiple high-dose sys-
temic administration of these cytokines is necessary
which is associated with adverse side effects [10,17]. To
overcome this limitation, several studies used cytokine-
expressing MSCs to mitigate cancer progress in tumor
models including melanoma [18-20]. Therefore, in this
study we aimed to investigate antitumor activity of
φC31/pBt modified murine ADSCs expressing IFNγ and
TRAIL individually, or co-expressing Trail/IFNγ in vitroand in mouse subcutaneous or lung metastasis models
of melanoma.
Results
Characterization of murine ADSCs
The authenticity of ADSCs was verified by differentiation
experiments (Figure 1) along with immunophenotypic
analysis of surface antigenes (Figure 2). ADSCs were iso-
lated based on their adherence to the surface of culture
dishes. Isolated cells expanded rapidly and in the third
passage uniformed cells were obtained. Cells from passage
6 were used for characterization experiments. Plasticity of
ADSCs was confirmed by differentiation of isolated
ADSCs (Figure 1A) to adipocytes (Figure 1B), chondro-
cytes (Figure 1, C and D) and osteoblasts (Figure 1, E
and F). Appearance of red colored lipid vacuoles in Oil
red O staining, green colored mucopolisaccarides in
Alcian blue staining, purple colored proteoglycans in
Toluidin blue staining, red colored calcium deposits in
Alizarin red staining and black colored mineralized de-
posits in Von Kossa staining demonstrated successful dif-
ferentiation of ADSCs into three different cell lineages.
Immunotyping of ADSCs revealed expression of stem cell
markers CD73, CD90.1, CD105, CD146 and MSC-homing
marker CXCR4. Moreover, a small sub-population of
ADSCs showed a weak expression of stem cell markers
CD24 and CD133. We did not detect any expression of
surface markers CD11b, CD25, CD34, CD45 and CD309,
confirming that our ADSC preparations did not contain
any hematopoietic or endothelial cells (Figure 2).
Stable modification of ADSCs and melanoma B16f10 Cells
by DNA integrating vectors
There is little information available regarding nucleofec-
tion of murine ADSCs. In this study, we achieved a trans-
fection efficiency of ~71% using the Human MSC
Nucleofector kit with program X-001 and plasmid pMax
(a vector expressing EGFP) (Figure 3, A, Left). ADSCs ex-
pressing enhanced green fluorescent protein (EGFP), IFNγ,
TRAIL and co-expressing IFNγ/TRAIL are respectively re-
ferred to EGFP-ADSC, IFNγ-ADSC, TRAIL-ADSC and
IFNγ/TRAIL-ADSC. FACS analysis of ADSCs nucleofected
with pmhyGENIE-3-EGFP revealed that ~75% of ADSCs
were EGFP-positive after two weeks of culture under anti-
biotic selection (Figure 3, A, Right). Furthermore, a micro-
scopic evaluation of these cells confirmed their efficient
modification (Figure 3, B). Melanoma B16F10 cells, stably
transformed and grown for 2 weeks under geneticin or
zeocin selection, uniformly expressed Red fluorescent pro-
tein (RFP) (Figure 3, C) and EGFP (Figure 3, D) respect-
ively (referred as RFP-melanoma and GFP-melanoma).
High levels of IFNγ expression were confirmed by Western
blot analysis as indicated by a 19 kD band in IFNγ-ADSCs
(Figure 3, E). FACS analysis of cells stained with
Figure 1 Differentiation potential of murine adipose derived mesenchymal stem cells (ADSCs). A) Isolated ADSCs at passage 6. B)
Differentiation of murine ADSCs into adipocytes. Oil red O staining visualizes lipid vacuoles. C and D) Cartilage differentiation of ADSCs. Alcian
blue (C) and Toluidin blue staining (D) indicate successful differentiation of ADSCs into chondrocytes. Inlay shows negative control for Alician
blue staining. E and F) Osteogenic differentiation was confirmed by Alizarin red S (E) and Von Kossa staining (F). Red coloring in Alizarin red S
and black nodules in Von Kossa staining respectively, indicative of calcium and extra matrix deposits produced by ADSCs. ADSC = adipose derived
mesenchymal stem cell.
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relevant protein expression in TRAIL-ADSCs and the ab-
sence of TRAIL in EGFP-ADSCs (Figure 3, F).
Effect of IFNγ on viability and apoptosis of melanoma
cells and the possible involvement of JAK/STAT1
dependent signaling pathway
To evaluate the effect of IFNγ on the proliferation of
melanoma cells we incubated B16F10 cells with 100 μl
of culture medium (CM) supernatant from IFNγ-
ADSCs. We determined the IFNγ concentration by
ELISA at about 1800 pg per mL of CM. We evaluated
the Melanoma cell proliferation and apoptosis by the 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) and Annexin V apoptosis assays. For MTT
assay, melanoma cells were incubated in CM from either
EGFP-ADSCs or IFNγ-ADSCs. Zeocin, a proliferation in-
hibitor, was used as a positive control (104 μg/mL) to
monitor apoptosis. Recombinant mouse IFNγ was used to
evaluate the effect of purified IFNγ on the proliferation ofmelanoma cells. All samples were compared to mock. The
results from MTT assays, shown in Figure 4A demon-
strated a statistically significant decrease in viability of
these melanoma cells, similar to the bioactivity effect of
purified mouse IFNγ (ANOVA, P < .001; Mean percent are
shown on Additional file 1: Table S1). As a subsequent step,
we assessed the potential of IFNγ on apoptosis of melan-
oma cells using Annexin V apoptosis assay. Results shown
in Figure 4, B and C indicated that incubation of melanoma
cells with IFNγ-containing CM induces early apoptosis of
melanoma cell over the incubation period in a statistically
significant manner (ANOVA, P < .001). The mean percent-
age of early apoptosis in melanoma cells during the incuba-
tion period of 24 hours with supernatant from IFNγ-ADSC
increased from ~18 to ~43% while melanoma cells treated
with mock supernatant showed only ~11 to ~17% of early
apoptosis (Additional file 1: Table S2). Additionally, we in-
vestigated whether IFNγ produced by IFNγ-ADSCs can ac-
tivate the JAK/STAT1 dependent signaling pathway in
melanoma cells. For this purpose we prepared two types of
Figure 2 Representative fluorescence-activated cell sorting (FACS) analysis of surface markers expressed by murine ADSCs cultured at
Passage 6. One experimental representative of three is shown. Cells were incubated with different monoclonal antibodies conjugated with either
fluorescein isothiocyanate (FITC) or phycoerythrin (PE). White histograms correspond to cells stained with antibodies against mouse surface
epitopes. Staining with the appropriate IgG isotype control antibody is shown in orange. Murine ADSCs were positive for stem cell markers like
CD73, CD90.1, CD105, CD146 and MSC-homing marker CXCR4. A small sub-population of ADSCs also expressed stem cell markers like CD24 and
CD133. ADSCs were negative for hematopoietic markers like CD11b, CD25, CD34, CD45 and the endothelial marker CD309. ADSC = adipose
derived mesenchymal stem cell; IgG = immunoglobulin G; CXCR4 = Chemokine Receptor type 4.
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of cells contained the firefly luciferase gene under direct
repeats of the interferon-stimulated response element
(ISRE) and a minimal TA promoter (referred herein as
ISRE/FL-melanoma cells). The second set of melanoma
cells were modified to constitutively express firefly lucifer-
ase under the control of a cytomegalovirus (CMV) enhan-
cer, a chicken beta actin and rabbit beta globin intron
(CAG) promoter (referred to as FL-melanoma cells and
used as positive control cells). FL-melanoma and ISRE/
FL-melanoma cells were incubated with supernatants
from either EGFP-ADSCs or IFNγ-ADSCs for 48 hours.
The analysis of the visible luminescence signal intensity
clearly demonstrated IFNγ-induced Jak/STAT-mediated
signal activation in ISRE/FL-melanoma cells (Figure 4D).Bioactivity of TRAIL and In Vitro effect of IFNγ on
sensitization of melanoma cells
To explore the bioactivity of TRAIL, triplicate co-culture
experiments were performed. Wild type ADSCs (WT-
ADSCs) or TRAIL-ADSCs were co-cultured with CAOV-4,
Ej-138, MCF-7, or B16F10 cells (Figure 5A). We observed
an effect of murine TRAIL in CAOV-4 and Ej-138 lines.
The mean mortality rate increased in a statistically signifi-
cant manner from 13.41 ± 1.2 % to 33.72 ± 5.1 % and 6.36
± 0.6 % to 22.2 ± 2.4 % for CAOV-4 and Ej-138 respectively
(t-test, P < .001). TRAIL-ADSCs had no effect on the other
cell lines (t-test, P = .545 for MCF-7 and P = .28 for
B16F10). For the next step, we co-cultured melanoma cells
with either WT-ADSC or TRAIL-ADSC, in mock CM or
IFNγ-containing CM, and for 12 h and 48 h (Figure 5B).
Figure 3 (See legend on next page.)
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Figure 3 Stable modification of ADSCs and melanoma B16f10 cells with the use of DNA integrating vectors. A) Flow cytometric analysis of EGFP
expression by ADSCs. (Left plot) Mean percentage of EGFP-expressing ADSCs post 48 h of nucleofection with pmaxGFP vector, indicating efficient transgene
transfer into mouse ADSCs. (Right plot) Mean percentage of EGFP-positive ADSCs two weeks after nucleofection with pmhyGENIE-3 and hygromycin
selection. Results are representatives of triplicate experiments. B) Fluorescence microscopy image of EGFP-expressing ADSCs after nucleofection with
pmhyGENIE-3 and two weeks selection with hygromycin. C) Stable RFP-expressing melanoma cells after lipofection with pDsRed-attb-zeo/pCMVInt and three
weeks of zeocin selection. D) EGFP-expressing melanoma cells after lipofection with pBEB/pCMVInt and three weeks of geneticin selection. E)Western blot
analysis of IFNγ from ADSC cell lysates. Modified ADSCs were selected with hygromycin following nucleofection with either pmhyGENIE-3 (Lane 1) or
pmhyGENIE-3-IFNγ (Lane 2). Blotting was performed using a monoclonal antibody against mouse IFNγ. F) Cytofluorimetric evaluation of TRAIL expression in
ADSCs selected with geneticin following co-nucleofection with pBEB/pCMVInt (Violet histograms) and pBTB/pCMVInt (white histograms). ADSCs were stained
with a PE conjugated monoclonal antibody to mouse TRAIL. A single representative experiment of triplicates is shown. (Left plot) Surface staining of
TRAIL-ADSCs after 48 h of co-nucleofection. (Right plot) Surface staining of TRAIL-ADSCs after co-nucleofection and three weeks of geneticin selection.
PE = phycoerythrin.
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oma cells with either WT-ADSC or TRAIL-ADSC in the
presence of IFNγ reduced the melanoma cell numbers
(ANOVA, P < .001). Shorter incubation periods with or
without IFNγ had no effect on melanoma cell numbers
(Figure 5C).
Plasma levels of IFNγ after injection of IFNγ-producing
ADSCs to mice
ELISA was performed to evaluate the effect of stem cell
therapy on systemic levels of IFNγ at three time points
(days 10, 16, and 21). The systemic levels of IFNγ in all of
the experimental groups were below the detection level of
our ELISA assay, indicating very low plasma levels.
In Vivo effect of modified ADSCs on growth of
subcutaneous melanoma and melanoma pulmonary
tumors, and survival analysis of mice with melanoma
metastases
We examined the effects of modified ADSCs on signal
intensity of red fluorescence protein expressed by mel-
anoma cells in subcutaneous tumors or established lung
metastases and on survival. For each model, mice were
randomly divided into the following five experimental
groups: injected with (a) PBS (control group), (b) EGFP-
ADSCs, (c) TRAIL-ADSCs, (d) IFNγ-ADSCs and (e)
IFNγ/TRAIL-ADSCs. Each group consisted of 6 mice
and the experiment for metastasis models was per-
formed in duplicate. There was no observed adverse
health effect related to the injection of ADSCs. In vivo
optical imaging of mice with subcutaneous melanoma
revealed a statistically significant reduction of melanoma
tumor growth detected by red fluorescent signal in groups
co-injected with IFNγ-expressing ADSCs (ANOVA,
P < .001, Figure 6A). There was no additive effect on
tumor ablation when IFNγ/TRAIL-ADSCs were co-
injected with the melanoma cells, indicating that presence
of IFNγ is solely responsible for tumor reduction (Figure 6,
A and D, left panel). Co-inoculation of melanoma cells
with EGFP-ADSC (ANOVA, P = .592) or TRAIL-ADSC
(P = .798) did not alter tumor growth. In lung metastaticmodels, metastatic colonies were observed in all treatment
groups. Using ex vivo imaging we noticed the presence of
several internal colonies that were not visible on the surface
of the lungs (Figure 6B). However, the colony size and num-
ber was reduced in mice treated with IFNγ-ADSCs and
IFNγ/TRAIL-ADSCs in a statistically significant manner
(ANOVA, P < .001, Figure 6, C and D, right panel). There
was no change in tumor size of mice treated
with EGFP-ADSCs (P= .216) or TRAIL-ADSCs (P= .907,
Figure 6, C and D, right panel). We examined whether gen-
etically modified ADSC (GM-ADSC) treatments improved
the overall survival of mice with melanoma lung metastases.
Treatment of mice with IFNγ-ADSCs or IFNγ/TRAIL-
ADSCs demonstrated a statistically significant increase in
the median survival of melanoma bearing mice, while most
of the animals in other groups died by day 40 (Figure 7A).
Results from the Pairwise log-rank test indicated there was
no difference between survival of mice treated with
IFNγ-ADSCs or IFNγ/TRAIL-ADSCs (Additional file 1:
Table S3). Results from immunohistochemistry (IHC)
and TUNEL staining shown in Figure 7, B and C indi-
cated a statistically significant decrease in melanoma
cell proliferation (Ki67; P < .001), tumor vasculature
(CD31; P < .001) and a statistically significant increase
in melanoma cell apoptosis (TUNEL; P < .001). Immu-
nostaining of pulmonary tumor sections revealed that
injected IFNγ-producing ADSCs upregulate PD-L1 ex-
pression in melanoma lung tumor cells (compared to
metastatic tumor samples from mice that received
EGFP-ADSCs or remained untreated) (Figure 7B). Dif-
ferentiation staining indicated there was no in vivo dif-
ferentiation of ADSCs from different groups into three
mesodermal lineages in tumor samples (Additional
file 2: Figure S1, available online). However, some
capillary-like structures of ADSCs were observed after
IHC for EGFP and PD-L1 (Additional file 3: Figure S2,
available online).
Murine ADSC homing
To evaluate the homing behavior of EGFP-ADSCs,
which had been co-injected with RFP-melanoma cells,
Figure 4 The bioactivity of IFNγ secreted from IFNγ-ADSCs. A) The sensitivity of melanoma B16F10 cells to IFNγ was evaluated by the MTT cell
viability assay. Melanoma cells were incubated in CM (culture medium) obtained from either EGFP-ADSCs (mock) or IFNγ-ADSCs for 3 days. Zeocin
(104 μg/mL) and purified mouse IFNγ (1000 pg/mL) were used respectively as a positive and sample control (all samples are compared to mock). Cell
viability after treatment is presented as a percentage relative to mock treated cells. ***P < .001. B) Representative FACS plots from Annexin V/propidium
iodide (PI) apoptosis assay showing an increase in early apoptosis of melanoma cells when cells are incubated in CM from IFNγ-ADSCs (Lower panels)
compared to CM from EGFP-ADSCs (Upper panels) for 12h and 24h incubation. One experimental representative of triplicates is shown. C) A bar graphs
summarizing the FACS results from annexin V/PI apoptosis assay in two time points demonstrating statistically significant increase in early apoptosis of
melanoma cells in the presence of IFNγ. Data represent mean values of three replicates in three independent experiments. ***P < .001. D) Monitoring the
induction of the STAT1 and STAT2 components of Jak/STAT-mediated signal transduction pathways. Melanoma cells were stably modified to express Firefly
luciferase (FL) under CMV enhancer-CAG promoter (FL-melanoma), or under direct repeats of the interferon-stimulated response element (ISRE) and a
minimal TA promoter (ISRE/FL-melanoma). ISRE/FL-melanoma cells were incubated in CM obtained from either EGFP-ADSCs (mock) or IFNγ-ADSCs for 48
hours and then ONE-Glo™ luciferase assay reagent was added to each sample. Luminescence imaging showed IFNγ-induced Jak/STAT-mediated signal
activation in melanoma B16F10 cells. (Left) FL-melanoma cells which were used as a positive control. (Middle) ISRE/FL-melanoma cells incubated with
supernatants from EGFP-ADSCs. (Right) ISRE/FL-melanoma cells incubated with CM from IFNγ-ADSCs. One experimental representative of triplicates
is shown.
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post intravenous injection using a In-Vivo imaging sys-
tem. We detected EGFP-ADSCs accumulating around the
tumors (Figure 8A), a finding confirmed by IHC analysis
of subcutaneous tumor sections (Figure 8A). Likewise, the
IHC analysis for IFNγ and TUNEL staining showed juxta-
position of IFNγ-ADSCs with melanoma cells (Figure 8E).
We also tracked homing of EGFP-ADSCs and IFNγ-
ADSCs to pulmonary B16F10 tumors. Melanoma noduleswere harvested at day 28 post melanoma cell injection.
The IHC analysis of melanoma lung tumor sections using
a polyclonal anti-EGFP Ab indicated homing of ~4.3 of
EGFP-positive cells to the melanoma metastases in the
lung (Figure 8, B and C). IHC analysis of melanoma me-
tastases using a monoclonal anti-mouse IFNγ Ab showed
~4.7 of IFNγ-positive cells per 1000 melanoma tumor
cells (Figure 8D). Detection of IFNγ in the melanoma lung
tumor samples confirmed prolonged expression of IFNγ
Figure 5 Apoptotic potential of TRAIL-producing ADSCs and the effect of IFNγ on sensitivity of melanoma B16F10 cells to TRAIL in
co-culture experiments. A)WT-ADSCs and TRAIL-ADSCs co-cultured with CAOV-4, Ej-138, MCF-7 and B16F10. Upper panel: Representative microscopy
images from each one of triplicate co-culture experiments. Inlays show the morphology of each cancer cell line. Lower panel: Representative FACS plots
showing a statistically significant increase in dead CAOV-4 and Ej-138 cells (Student t test, P< .001), implying bioactivity of TRAIL produced by murine modified
ADSCs. Each plot represents a mean value of three independent experiments. P values are two-sided. Scale bars =50 μm. B) FACS plots from co-culture
experiments demonstrated a decrease in proliferation of red fluorescent protein (RFP)-expressing melanoma cells in groups co-cultured with WT-ADSCs and
TRAIL-ADSCs only in the presence of IFNγ. Population of ADSCs and melanoma cells are shown in black and red respectively. One experimental representative
of triplicate independent experiments is shown. C) A FACS analysis (results depicted as bar graph) demonstrated a statistically significant decrease in
melanoma cell number co-cultured with both WT-ADSCs and TRAIL-ADSCs after addition of IFNγ-containing CM. However, the effect of IFNγ at 48 h of
incubation on melanoma cells co-cultured with WT-ADSCs was more significant (compared to melanoma cells co-cultured with TRAIL-ADSCs), implying IFNγ
does not effect the activity of TRAIL on melanoma B16F10 cells. Experiment was performed in triplicate. Error bars correspond to 95% confidence intervals.
P values are two-sided. ***P < .001 (ANOVA). WT =wild type.
Bahrambeigi et al. Molecular Cancer 2014, 13:255 Page 8 of 18
http://www.molecular-cancer.com/content/13/1/255by IFNγ-ADSCs, most of which homed to the melanoma
lung metastases and not to normal lung tissue (Figure 8F).
The effect of cell therapy on infiltration of CD4+, CD8+ ,
FOXP3+ and IL2+ Cells
We examined the infiltration of CD4+, CD8+, FOXP3+
and IL2+ cells to evaluate a potential participation of im-
mune cells in GM-ADSC therapy experiments. An IHC
analysis of metastatic lung tumors was performed at day
28 of the stem cell treatment. Metastatic lung tumors
treated by IFNγ revealed no statistically significant infil-
tration of CD4+, FOXP3+ and IL2+ cells compared to
control group (Figure 9A, upper panel, respective micro-
scopic images from control samples are shown), whereas
there was a statistically significant increase in CD8+ cells(ANOVA; P < .001, Figure 9B), indicating IFNγ-induced
infiltration of CD8+ T cells (Figure 9A, lower panel).
The effect of cell therapy on population of systemic CD4
+CD25+FOXP3+ T regulatory cells (Tregs)
Population analysis of peripheral blood mononuclear cell
(PBMC) isolated by Ficoll density gradient revealed two
separate populations of PBMCs; lymphocytes and mono-
cytes (Figure 9C, left panel). We initially analyzed
PBMCs and lymphocytes for CD4 (Figure 9C, right
panel) and subsequently CD4+ lymphocytes for CD25+
FOXP3+ by FACS analysis (Figure 9D). We noted that
the mean percentage of CD4+ cells significantly de-
creased in ADSC-injected groups in a statistically mean-
ingful manner (ANOVA, P = .021 for EGFP-ADSCs and
Figure 6 (See legend on next page.)
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Figure 7 Long-term survival and melanoma lung tumor analysis. A) Survival of mice with established pulmonary metastases of B16F10 melanoma
cells, intravenously injected with genetically modified ADSCs. An additional group of mice with established lung metastases derived from melanoma cells
received only PBS (control group). Survival was measured from the day of melanoma cell injection until the day of death. Survival curves were drawn by the
Kaplan-Meier method (n =6 in each treatment group). B) Representative microscopic images of immunohistochemistry (IHC) staining for cell
proliferation marker Ki67 (Inlays show negative control and positive controls), TUNEL staining for analysis of tumor cell apoptosis, IHC staining for
PD-L1 (Scale bars =50 μm), and IHC satining for neovasculature marker CD31 (Scale bar =100 μm). Microscopic images clearly shows injected
IFNγ-expressing ADSCs significantly upregulate PD-L1 expression in melanoma lung tumor cells (compared to untreated control and EGFP-ADSC
injected groups). C) Bar graphs showing statistically significant effect of IFNγ-ADSCs on growth of metastatic melanoma tumors. (Left) Quantification of
proliferation and apoptosis was performed by averaging percentage of positively stained cells to total cells within 10 randomly selected areas at x200
magnification. IFNγ-producing ADSCs significantly decreased the melanoma cell proliferation and increased tumor cell apoptosis in groups treated with
IFNγ-producing ADSCs in a statistically meaningful manner (ANOVA; p < .001). (Right) Quantification of angiogenesis was performed by counting the
number of vessels in 10 randomly selected areas of CD31 stained sections at x200 magnification. Results indicate statistically significant inhibition of
angiogenesis after injection of IFNγ-ADSCs. Each group consisted of four mice. ***P < .001 (ANOVA). The statistical tests were two-sided. PDL1 =
programmed cell death 1 ligand 1.
(See figure on previous page.)
Figure 6 In vivo and ex vivo red fluorescence optical imaging obtained with the In-Vivo FX Pro small-animal imaging system.
A) Representative red fluorescence in vivo images of subcutaneous melanoma bearing mice in different treatment groups. Red fluorescence protein
(RFP)-expressing melanoma cells in density of 2 × 106 were delivered either alone or concurrently with 7.5 × 105 of genetically modified ADSCs (GM-ADSCs).
Mice were anesthetized with isoflurane and images were captured using a multi-wavelength source with a 2 min exposure time. B) Upper image showing a
lung with RFP-melanoma lung metastases at day 28. Lower image, red fluorescence optical imaging of the same lung, indicating that some of
RFP-melanoma metastases are not superficially visible. C) Representative red fluorescence ex vivo images of dissected lungs in different treatment groups. On
day 0, 7.5 × 105 of RFP-melanoma cells were injected into the lateral tail vein of mice. Ten days later, mice were given PBS or 7.5 × 105 of GM-ADSCs by tail
vein injection. Mice were sacrified at day 28 for ex vivo optical imaging of lung samples, performed using a multi-wavelength source with a 2 min exposure
time. D) Quantification of fluorescent signal intensities was performed using the Bruker Molecular Imaging Software. Fluorescence intensity was expressed as
arbitrary units (AU) and was reported as a mean± SD in the bar graphs. (Left) Quantification of in vivo images (photons/s of subcutaneous tumor region). Bar
graphs indicate significant subcutaneous tumor regression in mice that were treated with IFNγ-expressing ADSCs, whereas tumors grew rapidly in the other
groups. (Right) Quantification of ex vivo images (photons/s of lung region). Bar graphs demonstrating reduced red fluorescence intensity in lung samples from
mice injected with IFNγ-expressing ADSCs, while red fluorescence intensity significantly increased in other groups. Each group consisted of six mice.
***P < .001 (ANOVA).
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Figure 8 Homing analysis of ADSCs for EGFP and IFNγ in subcutaneous tumor and lung metastatic models. A) Representative In vivo imaging of
green and red fluorescence optical imaging in mouse with subcutaneously co-injected EGFP-ADSCs and RFP-melanoma cells. Focal imaging indicates
aggregation of EGFP-expressing ADSCs around the melanoma cells in the tumor. IHC results of subcutaneous tumor sections for EGFP indicate that
melanoma cells and ADSCs are not mixed completely in the tumor. B and C) IHC analysis of EGFP + cells. Scale bars =25 μm. Panel B indicates a
representative microscopic image of staining for a section of the bone marrow derived from an EGFP transgenic mouse as a positive control. Inlay shows a
representative image of staining for a section of melanoma lung tumor from control group. Panel C shows a representative microscopic image of a
melanoma lung tumor section after injection of EGFP-ADSCs. D, E, and F) IHC analysis of IFNγ+ cells. Panel D) demonstrates a representative microscopic
image of a melanoma lung tumor section after injection of IFNγ-ADSCs. Scale bar =25 μm. Panel E) depicts a representative microscopic image of staining
for a section of subcutaneous melanoma tumor which indicates juxtaposition of IFNγ-ADSCs with melanoma cells. Scale bar =50 μm. The Inlay shows
representative image of TUNEL staining for IFNγ-ADSC/melanoma mixed tumor samples which also confirm position of IFNγ-ADSCs alongside the
melanoma cells. Panel F) Representative image which demonstrates both melanoma lung tissue and normal lung tissue. The image indicates that most
of IFNγ-ADSCs homed into melanoma lung tissue rather than normal lung tissue. Scale bar =50 μm.
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Figure 9E). Moreover, our results indicated that the
population of Tregs in mice treated with IFNγ-ADCS
(P =0.109) and IFNγ/TRAIL-ADSCs (P =0.797) were
comparable to the population of Tregs in normal mice.
In contrast, the population of Tregs were increased sig-
nificantly in a statistical manner in mice with establishedB16F10 lung metastases, which were injected with PBS
only, EGFP-ADSCs or TRAIL-ADSCs (ANOVA, P < .001,
Figure 9E).
Discussion
In the present study, we demonstrated that φC31 and/or
pBt mediated non-viral gene transfer provides prolonged
Figure 9 Determination of immune effectors following stem cell therapy. A) Infiltration of immune cells into the melanoma lung tumors. The
lung tumors stained with monoclonal antibodies specific for mouse CD4, FOXP3, IL2 and CD8. Only respective images of CD4+, FOXP3+ and IL2+ cells
from control samples are shown as there was no statistically significant difference between groups. Black arrows denote FOXP3+ and Il2+ cells. Results
show significant infiltration of CD8+ cell into the melanoma lung tumors after injection of IFNγ-expressing ADSCs. Scale bars =50 μm. B) As shown in
the bar graphs, mean number of CD8+ cells significantly increased in metastatic melanoma tumors of mice treated with IFNγ-ADSCs in a statistically
meaningful manner. N =6; ***P < .001. C and D) Representative FACS plots for analysis of systemic CD4+ and regulatory T cells in peripheral blood
obtained from the sub-ocular region of mice with established melanoma metastases. In addition, blood samples were taken from normal mice to
measure normal number of CD4+ and Tregs. C) Left plot is representative FACS plot showing two distinct populations of PBMCs: lymphocytes and
monocytes. Right plot is representative FACS plot indicating CD4 positive PBMCs. D) CD4+ lymphocytes were analyzed for expression of CD25 and
FOXP3 by flow cytometry. Representative plots indicating analysis of Tregs in Normal, Control, EGFP-ADSCs and IFNγ-ADSCs. E) The percentage of
CD4+ cells indicated a statistically significant decreased systemic level of CD4+ cells in ADSC-injected groups. The plot also shows a statistically
significant decrease in the percentage of Tregs in the peripheral blood of mice with melanoma metastases treated with IFNγ-producing ADSCs.
This percentage is comparable with systemic regulatory T cells of normal mice (P = .109; IFNγ-ADSCs compared to normal mice). N =6; ***P < .001,
**P < .01, *P < .05.
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http://www.molecular-cancer.com/content/13/1/255and high levels of transgene expression in ADSCs. Both
the recombinase and the transposase systems worked
well for modification of ADSCs. However, genomic
modifications mediated by φC31 may result in chromo-
somal rearrangements [21], whereas pBt is deactivated
during the excision of the transposon from the helper-
independent pmhyGENIE-3 construct [6]. We observed
robust levels of IFNγ and TRAIL expression in GM-
ADSCs conferring upon them the ability to be efficiently
used for cancer therapy. We also demonstrated that ex-
ogenously administered ADSCs survive and proliferate
in the tumor environment. When co-injected with mel-
anoma cells, ADSCs mostly stayed along with melanoma
cells. We explored the effect of TRAIL-ADSCs and we
showed that murine TRAIL, with a homology of 65% to
human TRAIL is active on human CAOV-4 and Ej-138
cell lines [22]. However, certain tumor cells such as mel-
anoma B16F10 and human MCF-7 breast cancer cell
lines used in this study are not amenable to TRAIL-
mediated apoptosis [23]. IFNγ may sensitize cancer cells
to TRAIL-induced apoptosis by upregulating Caspase-8
through a Stat1/IRF1 dependent pathway [11-16]. Still,
we did not observe sensitization of melanoma cells to
TRAIL in the presence of IFNγ. Therefore, melanoma
resistance is probably based upon lower expression of
functional death receptors (DR1 and DR2) [24]. Actually,
a recent study suggests the role of NFκB-mediated in-
flammatory signals through the death receptor DR5
which may promote malignant behaviors of melanoma
cells [24]. Interestingly, the effect of IFNγ on melanoma
B16F10 cells was remarkable. IFNγ has been clinically
applied to treat a variety of malignancies [8]. Phase I tri-
als of IFNγ gene transfer into cancer cells in patients
with metastatic melanoma have been performed, albeit
with low therapeutic efficacy [25-27]. Furthermore, it
has been shown that human IFNγ produced by genetic-
ally modified MSCs was able to inhibit proliferation and
induce apoptosis of human leukemia K562 cells in vitro
[28]. We demonstrated that IFNγ secreted by GM-
ADSCs is able to directly affect melanoma cells in vitro,
probably through activation of JAk1/Stat1 pathway [29].
Moreover, co-injection of IFNγ-ADSCs with melanoma
cells reduced the growth of subcutaneous melanoma tu-
mors. More importantly, intravenously injected IFNγ-
ADSCs significantly reduced growth of pre-established
melanoma lung metastases. In addition, systemic deliv-
ery of IFNγ-ADSCs does not elevate IFNγ amounts in
blood circulation, suggesting local expression of IFNγ.
We also explored the anti-tumor effects of IFNγ through
the activation of the immune response [30]. We noted a
significantly increased infiltration of CD8+ cells, while
the CD4+ and IL2+ cell count in the tumor environment
of IFNγ-ADSC treated mice remained constant. Add-
itionally, we confirmed IFNγ-induced overexpression ofPD-L1 in melanoma tumor cells [31,32]. These observa-
tions suggest a possible role of PD-L1 in impairing T cell
function because of; 1) the absence of infiltrated T
helper 1 cells (no statistically significant difference in
CD4+ and IL2+ cells) which is critical for the develop-
ment of cell-mediated immune response [32], and 2) the
accumulation of exhausted and inflamed CD8+ cells
which failed to produce IL2. The latter could explain
why melanoma metastases avoided complete eradication
in spite of significant infiltration of CD8+ cells [33]. Ac-
tually, CD8+ T cells and IFNγ may induce the expres-
sion of indoleamine-2,3-dioxygenase (IDO) and PD-L1
in the melanoma tumor microenvironment, and inhibit
the activation of additional T cells trafficking [34].
Therefore, we hypothesize that the observed anti-tumor
effect was primarily due to apoptosis in the melanoma
tumor and tumor endothelial cells. A similar observation
has been reported by Kakuta et al., where they examined
effects of IFNγ receptor-deficiency and NK cell depletion
on the melanoma tumor growth and suggested that
IFNγ prevents the murine melanoma metastases by dir-
ectly inhibiting cell growth when the tumor mass is
small and in an earlier developmental stage [35]. It is
also noteworthy that the population of infiltrated
FOXP3+ cells in IFNγ-ADSC treated mice did not differ
to those in mice of other treatment groups, indicating
that the higher systemic Tregs (in control and EGFP-
ADSC injected mice) was possibly due to immunosup-
pression mediated by tumor progression [36]. Therefore,
intravenous injection of IFNγ-ADSC indirectly main-
tained normal levels of systemic Treg through inhibition
of melanoma growth [36]. However, systemic injection
of GM-ADSCs showed immunosuppressive properties
probably associated with PD-L1 expression by ADSCs
[37]. The selective blockage of PD-L1 may be a potential
strategy to improve the therapeutic value of IFNγ-
producing ADSCs for melanoma treatment [38].
We were able to show that systematically transplanted
ADSCs engrafted into tumor cells, however the fact that
stem cells also migrate to many other organs makes it dif-
ficult to trace them. In fact, there is no clear consensus
amongst researchers where else such treated stem cells
end up after injection [39]. It is well known that systemic-
ally infused MSCs typically become trapped within the
lungs as the first micro capillary network they encounter
(pulmonary “first-pass” effect) [40]. Within 24h MSCs mi-
grate to other organs, in particular the liver and also the
spleen [41,42]. Consecutively, MSCs appear at injured tis-
sue sites and tumors as well as bone marrow, liver and
spleen [43,44]. This redistribution attributes to the ob-
served reduction of MSCs present in the lungs, as does
cell death [45]. Kidd et al. showed that in addition to the
specific tropism of MSCs in tumor sites, some MSCs
remained in the lungs, as well as some disseminating into
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after tail vein stem cell injections, cells dissipated from the
animals and were undetectable within one week after in-
jection [47].
Studies have attempted to address the eventual fate of the
MSCs within tumor microenvironments. MSC may differ-
entiate towards tumor-associated fibroblast (TAF) pheno-
types [48]. In addition, MSCs may acquire endothelial-like
characteristics, but their involvement in vasculogenesis is
complex. Comşa et al. indicated that MSCs, negative for
CD31, have a clear tendency to form capillary-like struc-
tures in the presence of tumor-derived VEGF [49]. The
same proved true in our hands where ADSCs co-injected
with melanoma cells organized into capillary-like struc-
tures, whereas, they did not differentiate into three meso-
dermal lineages in the melanoma tumor environment.
In order to translate stem cell-based anticancer strat-
egies into clinical therapy, it is essential to identify and
minimize treatment-associated risks. Only with improve-
ments in safety, quality, and efficiency of stem cell/gene
therapy for inoperable or malignant tumors, clinical sce-
narios can be envisaged. For the first time we employed
DNA integrating vectors including PhiC31and PiggyBac
transposase systems for safe and stable modification of
MSCs. We modified ADSCs to produce IFNγ and
TRAIL. Then evaluated antitumor effects of cytokine-
producing GM-ADSCs in murine models of melanoma.
The present study is the first in vivo attempt to use
ADSCs as a vehicle for IFNγ-mediated immunotherapy
and demonstrates the potential of non-virally modified
IFNγ-ADSCs for melanoma cancer therapy. This may
have a significant role in the management of cancer in
the future.Materials and methods
Isolation of ADSCs and culture
ADSCs were isolated from inguinal fat pads of 4–5 week-
old male C57BL6 mice (N = 8; 21.5 ± 0.7 g body weight).
Isolated cells were grown in culture medium (CM) con-
sisting of Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen Carlsbad, CA), 10% Fetal bovine serum (FBS;
Invitrogen Carlsbad, CA), 1 g/L glucose, 1% L-glutamine,
and 1% penicillin-streptomycin (Invitrogen Carlsbad, CA).
For details please see Additional file 1.ADSCs differentiation
ADSCs cultured at passage 6 were used for adipogenic,
osteogenic, and chondrogenic differentiation. As a first step,
cells were cultured for 3 weeks in differentiation medium
and consecutively stained with Oil red O, Alizarin red S,
Von Kossa S, Alcian blue, and Toluidine blue. For a detailed
description of the experiments please see Additional file 1.Immunotyping of ADSCs
Immunotyping of surface markers was performed in passage
6 with BD Calibur™ (Becton Dickinson San Jose, CA) using
monoclonal antibodies against mouse CD11b, CD24, CD34,
CD45, CD73, CD90.1, CD105, CD133, CD146, CD309 and
CXCR4 (all form eBioscience, San Diego, CA). A total of
5 × 105 cells from passage 6 were incubated with each anti-
body (Ab) in PBS with 3% bovine serum albumin (BSA;
Sigma, St. Louis, MO) for 40 min at 4°C. The Cells were
then washed with PBS and fixed with BD fixation reagent
(BD Biosciences, San Jose, CA sciences). Analysis of the
FACS data was carried out with a FlowJo software version
10 (Treestar, OR).Vector construction
Plasmids pCAG-DsReds [21], pCMVInt [6], pDRBB2 [50],
pBEB [6], pISRE-TA-Luc (Clontech, Mountain View, CA),
pBLB [6], pmhyGENIE-3 [51], coding sequences (CDS) of
murine full-length IFNγ, TRAIL and the sequence of
SV40 Promoter were used in this study. The plasmid
pBEB (carrying the attB, the enhanced green fluorescent
protein [EGFP] reporter gene) and the vector pmhy-
GENIE-3 (containing EGFP gene, a hyperactive self inacti-
vating piggyBac sequence and piggyBac transposon) were
used as a control plasmids for integrase and transposase
systems. We prepared the vector pDsRed-attb-zeo (carry-
ing eRFP, attB, eukaryotic zeocin resistance gene) using
the plasmid pCAG-DsReds (expressing the Red fluores-
cent protein [eRFP] reporter gene), the plasmid pDRBB2
(carrying attB and antibiotic resistance gene for zeocin
under the prokaryotic T7 promoter) and a synthesized se-
quence of T7 promoter. The vector pBTB (carrying attB
and antibiotic resistance gene for G418 and a murine full-
length TRAIL) was prepared using the vector pBLB (carry-
ing the attB and firefly luciferase [FL] under a chicken
beta actin and rabbit beta globin intron [CAG] promoter)
and synthesized murine TRAIL coding sequence (CDS;
protein ID =NP_033451.1). The plasmid pISRE-TA-Luc-
attB was prepared using the vector pISRE-TA-Luc
(carrying FL gene located downstream of ISRE enhancer
element and a minimal TA promoter; Clontech, Palo Alto
CA) and pBLB. All integrase-related constructs were co-
transfected with the plasmid pCMVInt (producing φC31
integrase) to achieve stable cell modification. Plasmids
pDsRed-attb-zeo, pmhyGENIE-3 and the coding sequence
of the full-length murine IFNγ (protein ID =NP_032363.1)
were used for construction of pmhyGENIE-3-IFNγ. CDS of
murine full-length IFNγ, TRAIL and the sequence of SV40
Promoter with pertinent restriction sites were synthesized
by Generay Biotech (Co., Ltd). All vectors were purified by
EndoFree® plasmid maxi kit (Qiagen, Valencia, CA) before
transfection. For additional information on vector construc-
tion please see Additional file 1.
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expression
Nucleofection was perfomed by nucleofector device 2b
(Amaxa Biosystems) using the Human MSC Nucleofector
kit (Amaxa Biosystems) with program X-001 (mouse T
cells). About 2 μg of DNA plasmid and 5 × 105 ADSCs
were used for each nucleofection experiment and done in
triplicate for each plasmid construct. The vector pMAX
was utilized for evaluation of nucleofection efficiency.
ADSCs modified with pBEB/pCMVInt, pBIB/pCMVInt,
pmhyGENIE-3, and pmhyGENIE-3-IFNγ are referred to as
EGFP/Int-ADSC, TRAIL-ADSC, EGFP-ADSC and IFNγ-
ADSC respectively. TRAIL-ADSCs were modified with
pmhyGENIE-3-IFNγ to generate ADSCs co-expressing
TRAIL and IFNγ (referred as IFNγ/TRAIL-ADSC). After
each nucleofection, 500 μl of CM was added to each
nucleofector cuvette and cells were seeded into 6 well plates
at 37°C in 5% CO2. Forty eight hours after each nucleofec-
tion, selection with related resistant antibiotic was initiated.
ADSCs co-nucleofected with the vectors pBEB/pCMVInt
(EGFP/Int-ADSC) and pBTB/pCMVInt (TRAIL-ADSC)
were exposed to 1000 μg/mL of G418 sulfate (Roche,
Indianapolis, IA) for two weeks and maintained in CM with
800 μg/mL of G418 sulfate. ADSCs nucleofected with the
plasmids pmhyGENIE-3 (GFP-ADSC) and pmhyGENIE-3-
IFNγ (IFNγ-ADSC) were selected with 200 μg/mL of
hygromycin (Roche, Indianapolis, IA) for about 10 days and
maintained under selection pressure with 100 μg/mL of
hygromycin, giving rise to EGFP-ADSCs and IFNγ-ADSCs.
After about 2 weeks 15 × 104 of TRAIL-ADSCs were
nucleofected with pmhyGENIE-3-IFNγ and selected with
hygromycin to create TRAIL/IFNγ co-expressing ADSCs
(TRAIL/IFNγ-ADSCs). These cells were maintained in a
CM containing G418 (800 μg/mL) and hygromycin
(100 μg/mL). Surface and intracellular staining of TRAIL-
ADSCs and EGFP/Int-ADSC (control) were done with
anti-TRAIL Ab (eBioscience, San Diego, CA). Expression of
IFNγ was confirmed by Western blot. Protein extraction
was performed by lysing EGFP-ADSCs and IFNγ-ADSCs
with Cell lysis buffer (Sigma, St. Louis, MO) supplemented
with a protease inhibitor cocktail (100 μg/mL; Sigma, St.
Louis, MO). Proteins were separated in 12% SDS PAGE
and transferred to nitrocellulose membrane (Amersham
Biosciences/GE Healthcare, Pittsburgh, PA). The mem-
brane was blocked in buffer containing PBS, 10% powdered
nonfat milk (Sigma, St. Louis, MO), and 0.05% Tween-20
(Sigma, St. Louis, MO). Blotting was performed with a
monoclonal rabbit anti-mouse IFNγ Ab at dilution of
1:1000. After twice washing the membrane with blocking
buffer, blotting continued using a horseradish peroxidase
(HRP)-conjugated anti-rabbit secondary antibody at 1:1000
dilution (Abcam, Cambridge, MA). Interferon-γ protein
band was detected after adding the enhanced chemilumin-
escence reagent (Amersham Biosciences/GE Healthcare,Little Chalfont) by an imaging system (Bruker Inc, Ettlingen,
Germany) using UV-Epi-Illumination source with 30 sec-
onds of exposure time.
Cancer cell culture, transfection, and selection
The mouse melanoma cell line B16F10, human breast
cancer cell line MCF-7, human bladder carcinoma derived
cell line Ej-138, and human ovarian carcinoma cell line
CAOV-4 were purchased from the Pasteur institute of
Iran. Cancer cells were maintained in CM at 37°C in a 5%
CO2 atmosphere. In this study, melanoma cells which
were modified with pBEB/pCMVInt and pDsRed-attb-
zeo/pCMVInt vectors are referred to GFP-melanoma and
RFP-melanoma cells respectively. Lipofection was used for
modification of melanoma cells. To create transgenic mel-
anoma B16F10, cells at a density of 2 × 105 per well in
triplicate for each group were seeded in 6-well plates.
After 24 h, cells were co-transfected with the vector
pBEB/pCMVInt, pBLB/pCMVInt, pISRE-TA-LUC-attb/
pCMVInt, and pDsRed-attb-zeo/pCMVInt using lipofec-
tamine 2000™ transfection reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. EGFP-
melanoma, FL-melanoma and ISRE/FL-melanoma were
selected, and maintained with 1000 μg/mL of G418. RFP-
melanoma was exposed to 400 μg/mL zeocin (Invitrogen,
Carlsbad, CA) and after about two weeks maintained in
CM with 100 μg/mL of zeocin.
Bioactivity of IFNγ and TRAIL produced by ADSCs
To study the effect of IFNγ-ADSC and TRAIL-ADSC on
melanoma B16F10 cells we evaluated proliferation and
apoptosis by MTT (Sigma, St. Louis, MO) and Annexin
V apoptosis (Roche, Indianapolis, IA) assays. MTT and
Annexin V apoptosis assays were performed as explained
in Additional file 1.
Monitoring the induction of the STAT1/2 components of
Jak/STAT-mediated signal transduction pathways
FL-melanoma and ISRE/FL-melanoma cells were seeded
into 12 well plates and incubated at 37°C in 5% CO2. Su-
pernatants from either EGFP-ADSCs or IFNγ-ADSCs
were added to these cells once they reached cell dens-
ities of 105 and 3 × 105 respectively. Two days later, a
volume of ONE-Glo™ luciferase assay reagent (Promega
Corp. Madison, WI) equal to that of the CM was added
to each well and samples were mixed thoroughly. Lumi-
nescence imaging was performed in an imaging system
(Bruker Inc, Ettlingen, Germany) using a UV-Epi-
Illumination source with a 15 min exposure time.
In vivo studies and optical imaging
Eight-week-old male C57BL/6 mice (30.1 ± 0.6 g body
weight) were purchased from the Pasteur institute of
Iran. Handling of the animals was performed according
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ics Committee of Isfahan University. For the subcutaneous
models of melanoma, 2 × 106 RFP-melanoma cells were de-
livered either alone or concurrently with 7.5 × 105 ADSCs
of each group described above, in 200 μl of PBS into the
right flank of the mice. The day of melanoma injection was
defined as day 0. At day 21, in vivo red fluorescence optical
imaging of subcutaneous RFP-melanoma bearing mice was
performed. Subsequently, all mice were euthanized via
pentobarbital overdose. In lung metastatic models, 7.5 ×
105 RFP-melanoma cells were delivered into the lateral tail
vein of twelve mice per group. Ten days later, the mice re-
ceived 7.5 × 105 of GM-ADSC in a volume of 200 μl of PBS
solution (control group received only 200 μl of PBS) by tail
vein injection. Six mice from each group were sacrificed
with pentobarbital overdose at day-28. Subsequently, their
lungs were dissected and ex vivo red fluorescence optical
imaging of lung samples was performed. The six remaining
mice from each group were kept alive for long-term sur-
vival analysis. For imaging, animals were anesthetized with
2% isoflurane and images were captured using a multi-
wavelength source with a 2 min exposure time in the In-
Vivo F Pro small-animal imaging system (Bruker Inc,
Ettlingen, Germany).Serum levels of IFNγ
Frozen serum collected from blood samples at days 10, 16,
and 21 was used in triplicate to quantify IFNγ protein
levels by enzyme-linked immunosorbent assay (ELISA)
using the mouse IFNγ Elipair kit (Abcam, Cambridge,
MA) in accordance with the manufacturer’s protocol.
Samples were analyzed at an absorbance of 450 nm with
minimal sensitivity of 15 pg/mL for IFNγ detection.Analysis of systemic CD4+ and CD4+CD25+FOXP3+
regulatory T cells (Treg)
Peripheral blood was taken from sub-ocular regions of
normal C57BL/6 mice (control samples) and lung meta-
static melanoma bearing mice at day 28 post melanoma
cell injection. Blood was overlaid onto 3 mL of
Ficoll-Paque and after centrifuging at 1800 rpm for
15 minutes, peripheral blood mononuclear cells
(PBMCs) at the interface were collected. PBMCs were
washed twice in PBS and then Treg cells were analyzed
using a mouse Treg detection kit (Miltenyi Biotec, Au-
burn, CA). PBMCs were stained with FITC-conjugated
monoclonal anti-mouse CD4 Ab and APC-conjugated
monoclonal anti-mouse CD25 Ab for 30 minutes at 4°C
in the dark. Subsequently, the PBMCs were incubated
with a PE-conjugated monoclonal anti-mouse Foxp3 Ab,
following the staining protocol provided by Miltenyi Bio-
tec. FACS data analysis was performed with BD Cell-
Quest Pro or FlowJo software.Histological analysis
Tissue sections were used for differentiation staining, ter-
minal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labeling (TUNEL) staining and immunohistochem-
istry (IHC) analysis. IHC was performed for EGFP, Ki67,
murine IFNγ, murine IL2, programmed cell death 1 ligand 1
(PD-L1; B7-H1), CD31, CD4+, CD8+ and FOXP3+. For a
detailed description of the experiments please see Additional
file 1.
Statistical analysis
Statistical analysis was performed using SPSS version 19
(SPSS Inc, Chicago, IL). The statistical differences between
the groups were assessed by Student t test, ANOVA, and
log-rank tests. Survival was defined as the date of melanoma
cell injection to the date of death. P values less than .05 were
considered statistically significant. All statistical tests were
two-sided. Data are presented as mean values with 95% con-
fidence intervals (CIs).
Additional files
Additional file 1: Supplementary data: Supplementary Methods,
Reference and Tables (Table S1, Table S2 and Table S3).
Additional file 2: Figure S1. Differentiation analysis of melanoma
tissues. Mouse fat tissue from the inguinal fat pad, murine
cartilage isolated from patellae and mouse bone tissue obtained from
a 8 week-old male C57BL6 mouse were used as positive controls (Left
panels). Representative images from melanoma/IFNγ-ADSCs co-injected
groups are shown (Right panels). Results indicated there was no in vivo
differentiation of ADSCs from different groups into three mesodermal
lineages. Scale bars = 50 μm. A) Oil red O staining. B) Alician blue
staining. C) Alizarin red staining. ADSC = adipose derived mesenchymal
stem cell, IFNγ = interferon gamma.
Additional file 3: Figure S2. Formation of capillary-like structures by
ADSCs in ADSCs/Melanoma co-injected groups. A) Representative
microscopic images of immunohistochemistry (IHC) staining for EGFP.
(Left) Melanoma/PBS (Right) Melanoma/EGFP. Capillary-like structures are
formed by EGFP expressing ADSCs. B) Representative microscopic
images of IHC staining for PD-L1. (Left) Melanoma/PBS (Right) Melanoma/
EGFP. Mesenchymal stem cells highly expressing PD-L1 have organized
capillary-like structures.
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